Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.

Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, Zuberbier T, Maurer M.

Allergy. 2012 Jul;67(7):943-50. doi: 10.1111/j.1398-9995.2012.02843.x. Epub 2012 May 15.

2.

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.

Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP.

Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29.

3.

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ.

Arthritis Rheum. 2008 Aug;58(8):2443-52. doi: 10.1002/art.23687.

4.

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopoulos JH, Weinstein SP, Mellis SJ, Kastner DL.

Arthritis Rheum. 2008 Aug;58(8):2432-42. doi: 10.1002/art.23620.

5.

[Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].

Lipsker D, Lenormand C.

Ann Dermatol Venereol. 2012 Jun;139(6-7):459-67. doi: 10.1016/j.annder.2012.03.012. Epub 2012 Apr 17. Review. French.

PMID:
22721478
6.

Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.

de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A.

Ann Rheum Dis. 2013 Oct;72(10):1634-8. doi: 10.1136/annrheumdis-2012-202192. Epub 2012 Oct 19.

PMID:
23087179
7.

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).

Gillespie J, Mathews R, McDermott MF.

J Inflamm Res. 2010;3:1-8. Epub 2010 Jan 19.

8.

Anakinra: an effective treatment in the Schnitzler syndrome.

Vandenhende MA, Bentaberry F, Morlat P, Bonnet F.

Joint Bone Spine. 2011 Dec;78(6):636-7. doi: 10.1016/j.jbspin.2011.03.021. Epub 2011 May 6.

PMID:
21550281
9.

MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.

Wittkowski H, Kuemmerle-Deschner JB, Austermann J, Holzinger D, Goldbach-Mansky R, Gramlich K, Lohse P, Jung T, Roth J, Benseler SM, Foell D.

Ann Rheum Dis. 2011 Dec;70(12):2075-81. doi: 10.1136/ard.2011.152496. Epub 2011 Sep 8.

10.

Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).

Hoffman HM.

Expert Opin Biol Ther. 2009 Apr;9(4):519-31. doi: 10.1517/14712590902875518 . Review.

PMID:
19344287
11.

Schnitzler syndrome: response to anakinra in two cases and a review of the literature.

Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W.

Int J Dermatol. 2009 Nov;48(11):1190-4. doi: 10.1111/j.1365-4632.2009.04151.x. Review.

PMID:
20064173
12.

Rilonacept in the treatment of chronic inflammatory disorders.

McDermott MF.

Drugs Today (Barc). 2009 Jun;45(6):423-30. doi: 10.1358/dot.2009.45.6.1378935. Review.

PMID:
19649332
13.

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, Wallace CA, Onel KB, Foell D, Wu R, Biedermann S, Hamilton JD, Radin AR.

Arthritis Rheum. 2013 Sep;65(9):2486-96. doi: 10.1002/art.38042.

14.

Canakinumab in Schnitzler syndrome.

Vanderschueren S, Knockaert D.

Semin Arthritis Rheum. 2013 Feb;42(4):413-6. doi: 10.1016/j.semarthrit.2012.06.003. Epub 2012 Aug 15.

PMID:
22901459
15.

[Schnitzler syndrome: case report, the experience with glucocorticoid and anakinra (Kineret) therapies and monitoring of systemic cytokine response].

Szturz P, Adam Z, Klabusay M, Fojtík Z, Kadanka Z, Stehlíková O, Chovancová J, Kalvodová L, Corbová D, Starý K, Neubauer J, Prásek J, Koukalová R, Rehák Z, Hájek R, Mayer J.

Vnitr Lek. 2011 Jan;57(1):97-112. Czech.

PMID:
21351669
16.

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.

de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW.

Ann Rheum Dis. 2006 Apr;65(4):542-4. Epub 2005 Aug 11.

17.

[Schnitzler syndrome: diagnostics and treatment].

Szturz P, Adam Z, Sedivá A, Fojtík Z, Corbová D, Neubauer J, Prásek J, Hájek R, Mayer J.

Klin Onkol. 2011;24(4):271-7. Review. Czech.

PMID:
21905617
18.

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A.

Ann Rheum Dis. 2009 Oct;68(10):1613-7. doi: 10.1136/ard.2009.108936. Epub 2009 Jul 26.

19.

Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).

Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, Lheritier K, Heike T, Hara T, Yokota S.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):302-9. Epub 2013 Feb 1.

PMID:
23380020
20.

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.

Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, Lohse P, Koitchev A, Deuter C, Foell D, Benseler SM.

Arthritis Rheum. 2011 Mar;63(3):840-9. doi: 10.1002/art.30149.

Items per page

Supplemental Content

Write to the Help Desk